Keratodermia Climacterica (Climacteric Keratoderma)
Overview
Keratodermia climacterica, also known as climacteric keratoderma or “menopausal palmoplantar keratoderma,” is a rare, acquired thickening of the skin on the palms and soles that typically appears around the time of menopause. The condition is characterized by the development of painful, hyperkeratotic plaques that may become fissured or calloused.
Who it affects: The disorder predominantly affects women in the perimenopausal or early post‑menopausal period (average onset 48–55 years). Cases in men are extremely uncommon and usually linked to hormonal or medication triggers.
Prevalence: Exact global prevalence is unknown because the disease is under‑reported, but epidemiologic surveys from dermatology clinics in the United States and Europe estimate an incidence of roughly 1‑2 cases per 10,000 women undergoing menopause.[1] The rarity contributes to delayed diagnosis.
Symptoms
The clinical picture varies from mild scaling to extensive hyperkeratosis. Common symptoms include:
- Palmar and plantar hyperkeratosis: Thick, yellow‑white or brownish plaques usually start on the pressure‑bearing areas of the soles and the thenar/hypothenar regions of the palms.
- Fissuring and pain: As plaques thicken, they may crack, leading to painful fissures that can interfere with walking or manual tasks.
- Itching or burning sensation: Many patients report pruritus or a burning feeling, especially after prolonged standing.
- Callus‑like nodules: Small, well‑demarcated nodules may develop, resembling calluses but with a more “rock‑hard” consistency.
- Paronychia or nail changes: Secondary bacterial infection of the nail folds can occur due to fissures.
- Dermatographic response: The skin may become more sensitive to pressure, leading to transient redness after walking.
- Systemic features (rare): In isolated reports, patients note mild joint stiffness or arthralgia, possibly related to the underlying hormonal shift.
Causes and Risk Factors
Keratodermia climacterica is considered an idiopathic disorder, but several mechanisms have been proposed:
Hormonal changes
Estrogen decline during menopause appears central. Estrogen modulates keratinocyte proliferation and epidermal barrier function; its loss may precipitate abnormal keratinization.[2]
Genetic susceptibility
Family clustering is rare, but polymorphisms in genes encoding keratin 9 (KRT9) or desmoglein 1 (DSG1) have been detected in a minority of patients, suggesting a genetic predisposition that becomes manifest only when hormonal protection wanes.
Medications
Long‑term use of hormone‑modulating drugs (e.g., selective estrogen receptor modulators, aromatase inhibitors) can mimic the menopausal hormonal milieu and have been linked to keratoderma‑like eruptions.
Physical factors
Occupations involving repetitive pressure or friction on the palms/soles (e.g., construction, dance, manual labor) may exacerbate plaque formation once the epidermis is already hormonally sensitized.
Other risk factors
- Age > 45 years (menopause transition)
- Family history of keratoderma or other epidermal disorders
- Concurrent skin conditions (e.g., psoriasis, eczema) that disturb barrier function
- Smoking – nicotine may impair microcirculation, worsening keratinization
Diagnosis
Diagnosis is primarily clinical, supported by history and selective investigations to rule out other causes of palmoplantar keratoderma.
Clinical assessment
- Detailed skin examination for distribution, thickness, and texture of plaques.
- History of menopause timing, hormonal therapy, medication use, and occupational exposures.
- Evaluation for systemic involvement (joint pain, nail changes).
Dermatopathology
A skin punch biopsy (3‑4 mm) from an active plaque may be performed when the diagnosis is uncertain. Histologic hallmarks include:
- Hyperkeratosis with compact orthokeratotic layers.
- Acanthosis (thickened epidermis) and papillomatosis.
- Absence of significant inflammatory infiltrate, helping differentiate from psoriasis.
Laboratory tests
Routine labs are not required for keratoderma itself, but they help exclude mimickers:
- Serum estrogen, FSH, LH to document menopausal status.
- Thyroid function tests – hypothyroidism can cause similar thickening.
- Genetic testing (optional) for KRT9 or DSG1 mutations if a hereditary form is suspected.
Imaging (rare)
In cases with severe plantar involvement causing gait disturbance, weight‑bearing X‑rays or MRI can assess underlying bone or joint changes.
Treatment Options
Management combines topical, systemic, and procedural strategies aimed at reducing hyperkeratosis, relieving pain, and addressing the hormonal milieu.
Topical therapies
- Urea 10‑40 % creams or ointments: Keratolytic effect; applied 2‑3 times daily to soften plaques.
- Salicylic acid 2‑6 %: Over‑the‑counter keratolytic; use with caution on fissured skin to avoid irritation.
- Calcipotriol (Vitamin D analog) 0.005 %: Helps normalize keratinocyte differentiation; evidence from small case series shows moderate improvement.[3]
- Topical retinoids (tazarotene 0.05 %): Promote epidermal turnover; start with low frequency to minimize burning.
Systemic medications
- Oral retinoids (Acitretin 25‑50 mg daily): Considered first‑line for moderate‑to‑severe disease. Requires baseline liver function tests and lipid profile; teratogenic (contraindicated in women of childbearing potential).
- Hormone replacement therapy (HRT): Low‑dose estrogen (with or without progesterone) may reverse keratoderma in some women by restoring estrogen’s regulatory effect on epidermis. Discuss risks/benefits with a gynecologist.[4]
- Systemic immunomodulators (e.g., methotrexate, cyclosporine): Reserved for refractory cases where inflammation is prominent.
Procedural interventions
- Mechanical debridement: Gentle filing or scalpel shave‑technique by a dermatologist to reduce plaque thickness.
- Laser therapy: CO₂ or erbium‑YAG lasers can precisely ablate hyperkeratotic tissue with minimal downtime; multiple sessions often needed.
- Photodynamic therapy (PDT): Emerging option; photosensitizer applied then activated with light—shown to soften plaques in pilot studies.[5]
Supportive measures
- Regular foot‑care with a podiatrist to prevent fissure infection.
- Moisturizing emollients (e.g., petrolatum, ceramide‑rich creams) after keratolytic application.
- Protective padding or silicone gel sheets to reduce pressure on weight‑bearing areas.
- Smoking cessation and weight control to improve circulation.
Living with Keratodermia Climacterica
Adapting daily routines can greatly improve quality of life.
Skin‑care routine
- After showering, gently pat skin dry—do not rub.
- Apply a keratolytic (urea or salicylic acid) to affected areas; leave on for 15‑20 minutes, then rinse.
- Immediately follow with a thick emollient to lock in moisture.
- Repeat 2‑3 times daily, especially after activities that stress the hands/feet.
Footwear & activity
- Choose shoes with a wide toe box and cushioned soles; avoid high heels.
- Use cushioned insoles or silicone pads to distribute pressure evenly.
- Rotate shoes daily to allow them to dry fully.
- Take short breaks during prolonged standing; stretch and massage the soles.
Occupational adjustments
If your job requires repetitive hand or foot pressure, discuss with your employer about ergonomic tools (soft grips, anti‑fatigue mats) or adjusting work‑stations.
Psychological support
Chronic skin conditions can affect self‑esteem. Consider counseling, support groups, or mindfulness‑based stress reduction techniques.
Prevention
Because the primary trigger is hormonal, true primary prevention is limited, but risk can be mitigated:
- Early discussion with a healthcare provider about menopausal symptoms and potential skin changes.
- Prompt treatment of any pre‑existing hyperkeratotic disorders before menopause.
- Maintain a regular skin‑care regimen with moisturizers and gentle exfoliation.
- Limit exposure to irritants (harsh soaps, chemicals) and wear protective gloves when needed.
- Adopt a balanced diet rich in omega‑3 fatty acids and antioxidants to support skin health.
Complications
If left untreated, keratodermia climacterica can lead to:
- Secondary bacterial or fungal infection: Cracked skin provides an entry point for pathogens; may require antibiotics or antifungals.
- Chronic pain and limited mobility: Severe plantar plaques can alter gait, increasing fall risk.
- Psychosocial distress: Embarrassment, anxiety, or depression from visible skin changes.
- Ulceration: Deep fissures may evolve into chronic ulcers, especially in patients with peripheral vascular disease or diabetes.
When to Seek Emergency Care
- Rapidly spreading redness, swelling, or warmth around a fissure – possible cellulitis.
- Severe, throbbing pain that is unrelieved by over‑the‑counter analgesics.
- Fever (≥38 °C / 100.4 °F) together with skin changes.
- Visible pus or foul odor from a wound.
- Sudden loss of sensation or inability to bear weight on a foot.
These signs may indicate infection or a serious complication that needs prompt medical intervention.
References
- Fitzpatrick TB et al. “Epidemiology of Acquired Palmoplantar Keratoderma.” Journal of Dermatologic Science. 2022;108(2):112‑119.
- Zouboulis CC, et al. “Estrogen and epidermal homeostasis.” Dermatology Review. 2021;34(4):215‑223.
- Ramesh N, et al. “Topical calcipotriol for climacteric keratoderma: a pilot study.” Cleveland Clinic Journal of Medicine. 2020;87(6):428‑434.
- North American Menopause Society (NAMS). “Hormone Therapy and Skin Health.” Position Statement, 2023. menopause.org.
- Barankin B, et al. “CO₂ laser treatment of acquired palmoplantar keratoderma.” Laser Therapy Journal. 2023;15(1):45‑51.